Compare Incyte Corporation (INCY) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Raytheon Technologies Corp — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Raytheon Technologies Corp trades at $223.68 (market cap $301.71B). The key difference: Raytheon Technologies Corp is far larger — about 12.3× Incyte Corporation's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RTX | |
|---|---|---|
Market Cap | $24.54B | $301.71B |
Sector | Health | Industrials |
52-Week High | $129.93 | $224.12 |
52-Week Low | $81.61 | $151.75 |
Enterprise Value | $20.04B | $332.26B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.
The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
